Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: 2-year results from the U-ENDURE Long-Term Extension studyEdward V. Loftus, Irina Blumenstein, Vipul Jairath et al.|Journal of Crohn s and Colitis|2025Cited by 8
Su1798 UPADACITINIB TREATMENT IS ASSOCIATED WITH IMPROVED CLINICAL AND QUALITY OF LIFE OUTCOMES IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE U-ENDURE LONG-TERM EXTENSIONDavid T. Rubin, Peter Bossuyt, Édouard Louis et al.|Gastroenterology|2024Cited by 0